



Europass Curriculum Vitae

Personal information

First name(s) / Surname(s) **Laura Mercatali**

Address(es) [REDACTED]

Telephone(s) [REDACTED] Mobil [REDACTED]

E-mail [REDACTED]

Nationality Italian

Date of birth [REDACTED]

Gender Female

Occupational field **Researcher in translational oncology**

Work experiences

Dates 01/2008→

Occupation or position held Senior Researcher; Lab referent for Osteoncology and rare Tumors

Main activities and responsibilities Laboratory biologist. Main activities: cell cultures, western blot, RT-PCR, RNA and DNA extraction. Article drafting and editing. Conceiving of translational studies. Coordination of a team of researchers. Projects topic: translational research in osteoncology

Name and address of employer Osteoncology and rare Tumors center, IRCCS Istituto scientifico romagnolo per lo studio e la cura dei tumori (IRST),
40, Piero Maroncelli rd, 47014 Meldola (FC) Italy

Type of business or sector Translational research and support to clinical diagnostic

Dates 1/2003-12/2007

Occupation or position held Junior Researcher

Main activities and responsibilities Laboratory biologist. Main activities: cell cultures, western blot, RT-PCR, RNA and DNA extraction. Article drafting and editing. Conceiving of translational studies. Projects topic: translational research in osteoncology

Name and address of employer Osteoncology and rare Tumors center, IRCCS Istituto scientifico romagnolo per lo studio e la cura dei tumori (IRST),
40, Piero Maroncelli rd, 47014 Meldola (FC) Italy

Type of business or sector Translational research and support to clinical diagnostic

Dates 03/2002-12/2002

Occupation or position held Voluntary worker

Main activities and responsibilities Laboratory biologist. Main activities: DNA extraction, RT-PCR, database implementation.

Name and address of employer Bioscience Laboratory, Ospedale Pierantoni, Via Forlanini 34 Forlì (FC), Italy

Type of business or sector Translational research and support to clinical diagnostic

Dates 01/2002 - 07/2002

Occupation or position held Researcher in experimental oncology

Main activities and responsibilities Laboratory biologist. Main activities: cell coltures, preclinical tests
Project topic: Cell-cycle deregulation in BALB/c 3T3 cells transformed by 1,2-dibromoethane and folpet pesticides.

Name and address of employer Istituto di Cancerologia, Università di Bologna Via filopanti, Bologna (Italy)

Type of business or sector Scientific research

Education and training

Dates 2013 jun-set
Type of qualification awarded VSRC at Princeton University
Principal subjects/occupational skills covered

Dates 2010→2014
Title of qualification awarded PHD
Principal subjects/occupational skills covered Pharmacology, Oncology

Name and type of organisation providing education and training Alma mater studiorum, Bologna University, Pharmacology Faculty

Dates 2003-2005
Title of qualification awarded MSC in toxicology (pharmaceutical curriculum) (maximum votation)
Principal subjects/occupational skills covered Toxicology, Pharmacology, Cancerogenesis process

Name and type of organisation providing education and training Alma mater studiorum, Bologna University, Pharmacology Faculty

Level in national or international classification

Dates 10/1996 - 12/2001

Title of qualification awarded Degree in Biomolecular biology
Principal subjects/occupational skills covered English language, cellular and molecular biology, Oncology, data analysis,

Name and type of organisation providing education and training Bologna University, Faculty of Bioscience

Level in national or international classification Second level Degree/ Specialistic Degree

Personal skills and competences

Mother tongue(s) Italian

Other language(s)

Self-assessment

European level (*)

English

Understanding				Speaking				Writing	
Listening		Reading		Spoken interaction		Spoken production			
B2	Independent user	B2	Independent user	B2	Independent user	B2	Independent user	B2	Independent user

(*) Common European Framework of Reference for Languages

Social skills and competences Able to work whit a group of people on a team, especially in laboratory where is required collaboration between different professional figures

Technical skills and competences	Good knowledge of laboratory techniques in particular cells cultures, western blot, PCR, DNA and RNA extraction and basic knowledge of citometry
Computer skills and competences	Good knowledge of Office packet, in particular word and excel. Basic Knowledge of statistical analysis programs, as SPSS and GraphPad
Driving licence	Car driving licence
Honor and award	<p>2012: win a travel grant of 400\$ for an abstract sent to IBCD 2012 (IBMS)</p> <p>2013: Winner of Francesco Baracca Ward as a I RST researcher</p> <p>2014: Winner of premio berlusconi Giovani ricercatori</p> <p>2017: winner of the grant financed by progetto Giovani Ricercatori" GR-2016-02364704 entitled An in vitro and ex vivo model of biomimetic regenerative devices to treat bone metastases and soft tissue tumors: BIOBOS PROJECT</p>
Publications	<p>H index: 17;</p> <p>More than 10 abstract accepted as a poster at national- International Oncology meeting as first author</p> <p>Papers</p>

Publications

- De Vita A, Recine F, Mercatali L, Miserocchi G, Liverani C, Spadazzi C, Casadei R, Bongiovanni A, Pieri F, Riva N, Amadori D, Ibrahim T. Myxofibrosarcoma primary cultures: molecular and pharmacological profile. *Ther Adv Med Oncol*. 2017 Dec;9(12):755-767. doi: 10.1177/1758834017737472. Epub 2017 Oct 28.
- De Vita A, Recine F, Mercatali L, Miserocchi G, Spadazzi C, Liverani C, Bongiovanni A, Pieri F, Casadei R, Riva N, Fausti V, Amadori D, Ibrahim T. Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents. *Int J Mol Sci*. 2017 Dec 8;18(12). pii: E2662. doi: 10.3390/ijms18122662.
- Bongiovanni A, Recine F, Celli M, Marcantognini G, Foca F, Liverani C, Fausti V, De Vita A, Miserocchi G, Mercatali L, Amadori D, Ibrahim T. Osteoblastic bone metastases from neuroendocrine tumor (NET) of unknown origin detected by 18fluorocholine PET/CT and its comparison with 68gallium-DOTATOC PET/CT: Case report and review of the literature. *Medicine (Baltimore)*. 2017 Nov;96(46):e8567. doi: 10.1097/MD.0000000000008567. Review.
- Recine F, Bongiovanni A, Casadei R, Pieri F, Riva N, De Vita A, Mercatali L, Liverani C, Spadazzi C, Miserocchi G, Fausti V, Amadori D, Ibrahim T. Primary leiomyosarcoma of the bone: a case report and a review of the literature. *Medicine (Baltimore)*. 2017 Nov;96(45):e8545. doi: 10.1097/MD.0000000000008545. Review.
- Miserocchi G, Mercatali L, Liverani C, De Vita A, Spadazzi C, Pieri F, Bongiovanni A, Recine F, Amadori D, Ibrahim T. Management and potentialities of primary cancer cultures in preclinical and translational studies. *J Transl Med*. 2017 Nov 7;15(1):229. doi: 10.1186/s12967-017-1328-z. Review.

6. Mercatali L, Spadazzi C, Miserocchi G, Liverani C, De Vita A, Bongiovanni A, Recine F, Amadori D, Ibrahim T. Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines. *J Vis Exp*. 2017 Sep 13;(127). doi: 10.3791/56311.
7. Mercatali L, La Manna F, Miserocchi G, Liverani C, De Vita A, Spadazzi C, Bongiovanni A, Recine F, Amadori D, Ghetti M, Ibrahim T. Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition. *Int J Mol Sci*. 2017 Jul 29;18(8). pii: E1655. doi: 10.3390/ijms18081655.
8. Recine F, Bongiovanni A, Riva N, Fausti V, De Vita A, Mercatali L, Liverani C, Miserocchi G, Amadori D, Ibrahim T. Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas. *Onco Targets Ther*. 2017 Feb 23;10:1155-1164. doi: 10.2147/OTT.S127955. eCollection 2017. Review.
9. Amadori D, Serra P, Masalu N, Pangan A, Scarpi E, Bugingo AM, Katabalo D, Ibrahim T, Bongiovanni A, Miserocchi G, Spadazzi C, Liverani C, Turri V, Tedaldi R, Mercatali L. Vitamin D receptor polymorphisms or serum levels as key drivers of breast cancer development? The question of the vitamin D pathway. *Oncotarget*. 2017 Feb 21;8(8):13142-13156. doi: 10.18632/oncotarget.14482.
10. Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of 18FDG-PET/CT. *Clin Lung Cancer*. 2017 Jul;18(4):415-420. doi: 10.1016/j.clcc.2016.11.004. Epub 2016 Nov 21
11. De Vita A, Miserocchi G, Recine F, Mercatali L, Pieri F, Medri L, Bongiovanni A, Cavaliere D, Liverani C, Spadazzi C, Amadori D, Ibrahim T. Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma. *Molecules*. 2016 Dec 3;21(12). pii: E1662.
12. Fici P, Gallerani G, Morel AP, Mercatali L, Ibrahim T, Scarpi E, Amadori D, Puisieux A, Rigaud M, Fabbri F. Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer. *Oncotarget*. 2017 Jan 10;8(2):2423-2436. doi: 10.18632/oncotarget.13682.
13. Liverani C, La Manna F, Groenewoud A, Mercatali L, Van Der Pluijm G, Pieri F, Cavaliere D, De Vita A, Spadazzi C, Miserocchi G, Bongiovanni A, Recine F, Riva N, Amadori D, Tasciotti E, Snaar-Jagalska E, Ibrahim T. Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model. *Biol Open*. 2017 Feb 15;6(2):133-140. doi: 10.1242/bio.022483. Erratum in: *Biol Open*. 2017 Feb 15;6(2):309.
14. Mercatali L, Spadazzi C, Miserocchi G, Liverani C, De Vita A, Bongiovanni A, Recine F, Amadori D, Ibrahim T. The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts. *Int J Mol Sci*. 2016 Nov 1;17(11). pii: E1827.
15. De Vita A, Mercatali L, Recine F, Pieri F, Riva N, Bongiovanni A, Liverani C, Spadazzi C, Miserocchi G, Amadori D, Ibrahim T. Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas. *Onco Targets Ther*. 2016 Oct 11;9:6233-6246. eCollection 2016. Review.
16. Ibrahim T, Ricci M, Scarpi E, Bongiovanni A, Ricci R, Riva N, Liverani C, De Vita A, La Manna F, Oboldi D, Serra P, Foca F, Cecconetto L, Amadori D, Mercatali L. RANKL: A promising circulating marker for bone metastasis response. *Oncol Lett*. 2016 Oct;12(4):2970-2975. Epub 2016 Aug 8.
17. Bongiovanni A, Monti M, Foca F, Recine F, Riva N, Di Iorio V, Liverani C, De Vita A, Miserocchi G, Mercatali L, Amadori D, Ibrahim T. Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR). *Support Care Cancer*. 2017 Jan;25(1):111-117. Epub 2016 Aug 27.
18. Mercatali L, La Manna F, Groenewoud A, Casadei R, Recine F, Miserocchi G, Pieri F, Liverani C, Bongiovanni A, Spadazzi C, de Vita A, van der Pluijm G, Giorgini A, Biagini R, Amadori D, Ibrahim T, Snaar-Jagalska E. Development of a Patient-Derived Xenograft (PDX) of Breast Cancer Bone Metastasis in a Zebrafish Model. *Int J Mol Sci*. 2016 Aug 22;17(8). pii: E1375. doi: 10.3390/ijms17081375.
19. Bongiovanni A, Riva N, Ricci M, Mercatali L, Liverani C, La Manna F, De Vita A, Cavaliere D, Pieri F, Oboldi D, Verdecchia GM, Amadori D, Ibrahim T. Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report. *BMC Cancer*. 2015 Dec 22;15:998. doi: 10.1186/s12885-015-2038-7.

20. Bongiovanni A, Riva N, Ricci M, Liverani C, La Manna F, De Vita A, Foca F, Mercatali L, Severi S, Amadori D, Ibrahim T. First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma. *Onco Targets Ther.* 2015 Dec 3;8:3613-9. doi: 10.2147/OTT.S91971. eCollection 2015.
21. Bongiovanni A, Ricci M, Riva N, Calpona S, Oboldi D, Pieri F, Cavaliere D, Mercatali L, Liverani C, La Manna F, De Vita A, Foca F, Gunelli E, Amadori D, Ibrahim T. Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: case report. *Future Oncol.* 2014 Dec;10(15):2423-7. doi: 10.2217/fon.14.159.
22. Bongiovanni A, Riva N, Calpona S, Ricci M, Gunelli E, Liverani C, La Manna F, De Vita A, Monti M, Severi S, Pieri F, Amadori E, Galassi R, Cavaliere D, Zaccaroni A, Tartaglia A, Lunedei V, Gardini A, Mercatali L, Amadori D, Ibrahim T. Metronomic capecitabine in gastroenteropancreatic neuroendocrine tumors: a suitable regimen and review of the literature. *Onco Targets Ther.* 2014 Oct 20;7:1919-26. doi: 10.2147/OTT.S68573. eCollection 2014.
23. Ricci M, Amadori E, Chiesa F, Bongiovanni A, Liverani C, Fabbri L, Falasconi MC, Casadei R, Oboldi D, Galassi R, Micheletti S, Severi S, Serra L, Pieri F, Calabrese L, Riva N, Calpona S, Gunelli E, Mercatali L, Amadori D, Ibrahim T. Single bone metastasis from adenocarcinoma of the lacrimal gland: a case report. *Future Oncol.* 2014 Aug;10(10):1735-9. doi: 10.2217/fon.14.36.
24. Chakrabarti R, Wei Y, Hwang J, Hang X, Andres Blanco M, Choudhury A, Tiede B, Romano RA, DeCoste C, Mercatali L, Ibrahim T, Amadori D, Kannan N, Eaves CJ, Sinha S, Kang Y. Δ Np63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. *Nat Cell Biol.* 2014 Oct;16(10):1004-15. doi: 10.1038/ncb3040. Epub 2014 Sep 21.
25. Ell B, Qiu Q, Wei Y, Mercatali L, Ibrahim T, Amadori D, Kang Y. The microRNA-23b/27b/24 cluster promotes breast cancer lung metastasis by targeting metastasis-suppressive gene prosaposin. *J Biol Chem.* 2014 Aug 8;289(32):21888-95. doi: 10.1074/jbc.M114.582866. Epub 2014 Jun 25.
26. Liverani C, Mercatali L, Spadazzi C, La Manna F, De Vita A, Riva N, Calpona S, Ricci M, Bongiovanni A, Gunelli E, Zanoni M, Fabbri F, Zoli W, Amadori D, Ibrahim T. CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems. *Bone.* 2014 Sep;66:214-22. doi: 10.1016/j.bone.2014.06.017.
27. Ibrahim T, Mercatali L, Amadori D. A new emergency in oncology: Bone metastases in breast cancer patients (Review). *Oncol Lett.* 2013 Aug;6(2):306-310. Epub 2013 Jun 4.
28. Ell B, Mercatali L, Ibrahim T, Campbell N, Schwarzenbach H, Pantel K, Amadori D, Kang Y. Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. *Cancer Cell.* 2013 Oct 14;24(4):542-56. doi: 10.1016/j.ccr.2013.09.008.
29. Ibrahim T, Mercatali L, Amadori D. Bone and cancer: the osteoncology. *Clin Cases Miner Bone Metab.* 2013 May;10(2):121-3. Review.
30. Amadori D, Mercatali L, Nanni O, Aglietta M, Alessi B, Gianni L, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI, Ibrahim T. What can we learn from the ZOOM trial?--Authors' reply. *Lancet Oncol.* 2013 Sep;14(10):e388-90. doi: 10.1016/S1470-2045(13)70295-X. No abstract available.
31. Mercatali L, Ricci M, Scarpi E, Serra P, Fabbri F, Ricci R, Liverani C, Zanoni M, Zoli W, Maltoni R, Gunelli E, Amadori D, Ibrahim T. RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study. *Int J Mol Sci.* 2013 May 23;14(6):10683-93. doi: 10.3390/ijms140610683.
32. Ibrahim T, Farolfi A, Mercatali L, Ricci M, Amadori D. Metastatic bone disease in the era of bone-targeted therapy: clinical impact. *Tumori.* 2013 Jan-Feb;99(1):1-9. doi: 10.1700/1248.13780. Review.
33. Ulivi P, Mercatali L, Casoni GL, Scarpi E, Bucchi L, Silvestrini R, Sanna S, Monteverde M, Amadori D, Poletti V, Zoli W. Multiple marker detection in peripheral blood for NSCLC diagnosis. *PLoS One.* 2013;8(2):e57401. doi: 10.1371/journal.pone.0057401. Epub 2013 Feb 26.
34. Ibrahim T, Liverani C, Mercatali L, Sacanna E, Zanoni M, Fabbri F, Zoli W, Amadori D. Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines. *Int J Oncol.* 2013 Apr;42(4):1263-70. doi: 10.3892/ijo.2013.1809. Epub 2013 Feb 6.

35. Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y, Li C, Chong M, Ibrahim T, Mercatali L, Amadori D, Lu X, Xie D, Li QJ, Wang XF. miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. *Nat Cell Biol.* 2013 Mar;15(3):284-94. doi: 10.1038/ncb2690. Epub 2013 Feb 10.
36. Ibrahim T, Farolfi A, Scarpi E, Mercatali L, Medri L, Ricci M, Nanni O, Serra L, Amadori D. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact. *Oncology.* 2013;84(3):150-7. doi: 10.1159/000345795. Epub 2012 Dec 19.
37. Ibrahim T, Mercatali L, Sacanna E, Tesei A, Carloni S, Ulivi P, Liverani C, Fabbri F, Zanoni M, Zoli W, Amadori D. Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. *Cancer Cell Int.* 2012 Nov 22;12(1):48. doi: 10.1186/1475-2867-12-48.
38. Chakrabarti R, Hwang J, Andres Blanco M, Wei Y, Lukačšinić M, Romano RA, Smalley K, Liu S, Yang Q, Ibrahim T, Mercatali L, Amadori D, Haffty BG, Sinha S, Kang Y. E1f5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. *Nat Cell Biol.* 2012 Nov;14(11):1212-22. doi: 10.1038/ncb2607. Epub 2012 Oct 21.
39. Korpai M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celià-Terrassa T, Mercatali L, Khan Z, Goodarzi H, Hua Y, Wei Y, Hu G, Garcia BA, Ragoussis J, Amadori D, Harris AL, Kang Y. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. *Nat Med.* 2011 Aug 7;17(9):1101-8. doi: 10.1038/nm.2401.
40. Ibrahim T, Sacanna E, Gaudio M, Mercatali L, Scarpi E, Zoli W, Serra P, Ricci R, Serra L, Kang Y, Amadori D. Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients. *Clin Breast Cancer.* 2011 Dec;11(6):369-75. doi: 10.1016/j.clbc.2011.05.001. Epub 2011 Jul 20.
41. Sacanna E, Ibrahim T, Gaudio M, Mercatali L, Scarpi E, Zoli W, Serra P, Bravaccini S, Ricci R, Serra L, Amadori D. The role of CXCR4 in the prediction of bone metastases from breast cancer: a pilot study. *Oncology.* 2011;80(3-4):225-31. doi: 10.1159/000327585. Epub 2011 Jul 5.
42. Mercatali L, Ibrahim T, Sacanna E, Flamini E, Scarpi E, Calistri D, Ricci M, Serra P, Ricci R, Zoli W, Kang Y, Amadori D. Bone metastases detection by circulating biomarkers: OPG and RANKL. *Int J Oncol.* 2011 Jul;39(1):255-61. doi: 10.3892/ijo.2011.1001. Epub 2011 Apr 13.
43. Mercatali L, Ibrahim T, Sacanna E, Flamini E, Scarpi E, Calistri D, Ricci M, Serra P, Ricci R, Zoli W, Kang Y, Amadori D. Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer. *J Clin Pharmacol.* 2012 Mar;52(3):361-9. doi: 10.1177/0091270010396710. Epub 2011 Mar 7.
44. Casoni GL, Ulivi P, Mercatali L, Chilosi M, Tomassetti S, Romagnoli M, Ravaglia C, Gurioli C, Gurioli C, Zoli W, Silvestrini R, Poletti V. Increased levels of free circulating DNA in patients with idiopathic pulmonary fibrosis. *Int J Biol Markers.* 2010 Oct-Dec;25(4):229-35.
45. Ibrahim T, Flamini E, Mercatali L, Sacanna E, Serra P, Amadori D. Pathogenesis of osteoblastic bone metastases from prostate cancer. *Cancer.* 2010 Mar 15;116(6):1406-18. doi: 10.1002/cncr.24896. Review.
46. Ibrahim T, Flamini E, Fabbri L, Serra P, Mercatali L, Ricci R, Sacanna E, Falasconi MC, Casadei R, Galassi R, Giannini M, Bazzocchi O, Calzolari F, Nunziatini R, Gaudio M, Maltoni M, Amadori D. Multidisciplinary approach to the treatment of bone metastases: Osteo-Oncology Center, a new organizational model. *Tumori.* 2009 May-Jun;95(3):291-7.
47. Ibrahim T, Barbanti F, Giorgio-Marrano G, Mercatali L, Ronconi S, Vicini C, Amadori D. Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study. *Oncologist.* 2008 Mar;13(3):330-6. doi: 10.1634/theoncologist.2007-0159.
48. Flamini E, Mercatali L, Nanni O, Calistri D, Nunziatini R, Zoli W, Rosetti P, Gardini N, Lattuneddu A, Verdecchia GM, Amadori D. Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. *Clin Cancer Res.* 2006 Dec 1;12(23):6985-8.

49. Santucci MA, Mercatali L, Brusa G, Pattacini L, Barbieri E, Perocco P. Cell-cycle deregulation in BALB/c 3T3 cells transformed by 1,2-dibromoethane and folpet pesticides. *Environ Mol Mutagen.* 2003;41(5):315-21.
50. Barbieri L, Brigotti M, Perocco P, Carnicelli D, Ciani M, Mercatali L, Stirpe F. Ribosome-inactivating proteins depurinate poly(ADP-ribosyl)ated poly(ADP-ribose) polymerase and have transforming activity for 3T3 fibroblasts. *FEBS Lett.* 2003 Mar 13;538(1-3):178-82.